Copyright
©The Author(s) 2022.
World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Table 3 Organization to Assess Strategies in Ischemic Syndromes 5: Fondaparinux vs Enoxaparin in non-ST elevation acute coronary syndrome patients undergoing percutaneous coronary intervention
| Outcome day 9 | Enoxaparin (n = 3072) | Fondaparinux (n = 3106) | Hazard ratio | P value |
| Death, MI, or stroke | 6.2 | 6.3 | 1.03 | 0.79 |
| Major bleeding | 5.1 | 2.4 | 0.46 | < 0.00001 |
| Catheter thrombosis | 0.4 | 0.9 | 3.59 | 0.001 |
- Citation: Khan MY, Ponde CK, Kumar V, Gaurav K. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J Cardiol 2022; 14(1): 40-53
- URL: https://www.wjgnet.com/1949-8462/full/v14/i1/40.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i1.40